Refine Results
- 必威体育赛事投注
- Applications and Industries
- Content Type
- Analysis Platform
- Language
1 - 11 of 11 results
Applied Filters
必威体育登录手机This study used the Agilent xCELLigence RTCA CardioECR system with human iPSC-derived cardiomyocytes (hiPSC-CMs) to evaluate cardiac safety/toxicity of antiviral drugs.
必威体育登录手机A demonstration of the use of the Agilent xCELLigence RTCA CardioECR system to compare functional profiles of contractility and electrophysiology between an PS-iPSC-CM disease model and its isogenic control.
Noninvasive and continuous monitoring of the perturbation of cellular growth following exposure to the cumulative toxicants present in water samples.
必威体育登录手机A demonstration of how the Agilent xCELLigence RTCA eSight real-time imaging platform can be used to monitor phagocytosis, using a model system comprising macrophages and E.coli cells conjugated to a pH-sensitive fluorescent dye.
必威体育登录手机A demonstration of how the Agilent xCELLigence RTCA eSight real-time imaging platform can be used to monitor induction of the unfolded protein response using a genetically encoded fluorescent sensor.
A demonstration of how the eSight combines the strengths of real-time impedance monitoring with those of live cell imaging, to increase the information richness of your proliferation assays while simultaneously reducing the workload.
To determine if the stimulation of endogenously expressed GPCRs can be monitored by the xCELLigence system, cells were stimulated with various receptor agonists, triggering either Gs-, Gi-, or Gq-mediated downstream signals.
必威体育登录手机Using the Agilent xCELLigence RTCA eSight to continuously monitor CAR T cell-mediatedkilling of cancer cells over the course of multiplae days.
必威体育登录手机This application note presents a method for improving human-induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) maturation using the Agilent xCELLigence RTCA ePacer system.
In this application note, we used the xCELLigence RTCA CardioECR system (CardioECR system) in conjunction with hiPS-CMs for the assessment of preclinical cardiac risks.
必威体育登录手机Using the Agilent xCELLigence RTCA system to assess both the selectivity and potency of the TCR-engineered TILs toward HLA restricted cells.